Wealthfront Advisers LLC Purchases 2,202 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Wealthfront Advisers LLC boosted its Regeneron stake by 37.1%, acquiring 2,202 shares to hold 8,142 shares worth about $6.285 million, while institutional investors collectively own roughly 83.31% of REGN.
• Regeneron beat Q1 expectations with $3.61 billion in revenue (up 19%) and $9.47 EPS, and management announced a $3 billion buyback plus a quarterly dividend of $0.94 ($3.76 annual), although the stock faces near‑term headwinds from weaker Eylea sales and a ~10% drop in GAAP net income.

Wealthfront Advisers LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 37.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,142 shares of the biopharmaceutical company's stock after acquiring an additional 2,202 shares during the period. Wealthfront Advisers LLC's holdings in Regeneron Pharmaceuticals were worth $6,285,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. WPG Advisers LLC boosted its holdings in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 25 shares in the last quarter. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals in the third quarter worth approximately $27,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $31,000. Caitlin John LLC bought a new position in Regeneron Pharmaceuticals in the third quarter worth approximately $34,000. Finally, FNY Investment Advisers LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $38,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 3.0%

REGN stock opened at $707.06 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.15 and a debt-to-equity ratio of 0.06. The stock's 50 day moving average is $756.81 and its 200-day moving average is $735.17. The firm has a market capitalization of $74.75 billion, a PE ratio of 17.23, a P/E/G ratio of 1.58 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts' consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter last year, the company earned $8.22 earnings per share. The company's revenue for the quarter was up 19.0% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.98 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.16%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. TD Cowen increased their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a "buy" rating in a report on Thursday, April 23rd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $800.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating on the stock in a report on Thursday. Barclays dropped their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating on the stock in a report on Thursday. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $825.68.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat expectations: Regeneron reported Q1 revenue up 19% to ~$3.6B and non‑GAAP EPS of $9.47, beating estimates, driven by strong Dupixent demand and Libtayo. This underpins near‑term top‑line momentum. Reuters: Regeneron beats quarterly results
• Positive Sentiment: $3 billion buyback announced and dividend declared: Management authorized up to $3B in share repurchases and declared a $0.94 quarterly dividend, both shareholder-friendly actions that support EPS and investor returns. Seeking Alpha: buyback mention
• Positive Sentiment: Pipeline progress could drive medium‑term upside: Management reported C5 program milestones (pivotal PNH enrollment complete, positive Phase III for cemdisiran in gMG) and potential multi‑indication launches as soon as late‑2026 — important optionality beyond core franchises. Yahoo: C5 milestones & pipeline
• Neutral Sentiment: Analyst target adjustments but mixed ratings: Several shops trimmed price targets (RBC to $762, Wells Fargo to $800, Truist to $796, Barclays to $917) while many retained buy/overweight stances — suggests analysts are tuning models post‑earnings but still see upside. TickerReport/Benzinga: price target moves
• Neutral Sentiment: Analysts trimmed near‑term forecasts: Firms modestly cut forecasts after Q1, reflecting product mix and competitive assumptions; important to watch updated guidance and modeling revisions. Benzinga: analysts cut forecasts
• Negative Sentiment: Market punished stock on Eylea weakness and competitive risk: U.S. high‑dose Eylea sales underperformed expectations and competition in the retina market is intensifying — this drove the immediate post‑earnings weakness despite the beat. Yahoo: Eylea sales miss
• Negative Sentiment: Q1 net income decline: GAAP net income fell ~10% to $727M year‑over‑year, reflecting some one‑time items and mix; investors sensitive to margin and profitability trends may see this as a near‑term headwind. Pharma‑Technology: net income falls

Insider Activity at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares of the company's stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the sale, the director directly owned 17,803 shares of the company's stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 3,774 shares of company stock valued at $2,942,738. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.